Cargando…

Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints

BACKGROUND: Adipose tissue-derived stem cells (ADSCs), a type of mesenchymal stem cells (MSCs), have great potential as therapeutic agents in regenerative medicine. Numerous animal studies have documented the multipotency of ADSCs, showing their capabilities to differentiate into tissues such as mus...

Descripción completa

Detalles Bibliográficos
Autores principales: Pak, Jaewoo, Chang, Jae-Jin, Lee, Jung Hun, Lee, Sang Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219585/
https://www.ncbi.nlm.nih.gov/pubmed/24289766
http://dx.doi.org/10.1186/1471-2474-14-337
_version_ 1782342604242812928
author Pak, Jaewoo
Chang, Jae-Jin
Lee, Jung Hun
Lee, Sang Hee
author_facet Pak, Jaewoo
Chang, Jae-Jin
Lee, Jung Hun
Lee, Sang Hee
author_sort Pak, Jaewoo
collection PubMed
description BACKGROUND: Adipose tissue-derived stem cells (ADSCs), a type of mesenchymal stem cells (MSCs), have great potential as therapeutic agents in regenerative medicine. Numerous animal studies have documented the multipotency of ADSCs, showing their capabilities to differentiate into tissues such as muscle, bone, cartilage, and tendon. However, the safety of autologous ADSC injections into human joints is only beginning to be understood and the data are lacking. METHODS: Between 2009 and 2010, 91 patients were treated with autologous ADSCs with platelet-rich plasma (PRP) for various orthopedic conditions. Stem cells in the form of stromal vascular fraction (SVF) were injected with PRP into various joints (n = 100). All patients were followed for symptom improvement with visual analog score (VAS) at one month and three months. Approximately one third of the patients were followed up with third month magnetic resonance imaging (MRI) of the injected sites. All patients were followed up by telephone questionnaires every six months for up to 30 months. RESULTS: The mean follow-up time for all patients was 26.62 ± 0.32 months. The follow-up time for patients who were treated in 2009 and early 2010 was close to three years. The relative mean VAS of patients at the end of one month follow-up was 6.55 ± 0.32, and at the end of three months follow-up was 4.43 ± 0.41. Post-procedure MRIs performed on one third of the patients at three months failed to demonstrate any tumor formation at the implant sites. Further, no tumor formation was reported in telephone long-term follow-ups. However, swelling of injected joints was common and was thought to be associated with death of stem cells. Also, tenosinovitis and tendonitis in elderly patients, all of which were either self-limited or were remedied with simple therapeutic measures, were common as well. CONCLUSIONS: Using both MRI tracking and telephone follow ups in 100 joints in 91 patients treated, no neoplastic complications were detected at any ADSC implantation sites. Based on our longitudinal cohort, the autologous and uncultured ADSCs/PRP therapy in the form of SVF could be considered to be safe when used as percutaneous local injections.
format Online
Article
Text
id pubmed-4219585
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42195852014-11-05 Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints Pak, Jaewoo Chang, Jae-Jin Lee, Jung Hun Lee, Sang Hee BMC Musculoskelet Disord Research Article BACKGROUND: Adipose tissue-derived stem cells (ADSCs), a type of mesenchymal stem cells (MSCs), have great potential as therapeutic agents in regenerative medicine. Numerous animal studies have documented the multipotency of ADSCs, showing their capabilities to differentiate into tissues such as muscle, bone, cartilage, and tendon. However, the safety of autologous ADSC injections into human joints is only beginning to be understood and the data are lacking. METHODS: Between 2009 and 2010, 91 patients were treated with autologous ADSCs with platelet-rich plasma (PRP) for various orthopedic conditions. Stem cells in the form of stromal vascular fraction (SVF) were injected with PRP into various joints (n = 100). All patients were followed for symptom improvement with visual analog score (VAS) at one month and three months. Approximately one third of the patients were followed up with third month magnetic resonance imaging (MRI) of the injected sites. All patients were followed up by telephone questionnaires every six months for up to 30 months. RESULTS: The mean follow-up time for all patients was 26.62 ± 0.32 months. The follow-up time for patients who were treated in 2009 and early 2010 was close to three years. The relative mean VAS of patients at the end of one month follow-up was 6.55 ± 0.32, and at the end of three months follow-up was 4.43 ± 0.41. Post-procedure MRIs performed on one third of the patients at three months failed to demonstrate any tumor formation at the implant sites. Further, no tumor formation was reported in telephone long-term follow-ups. However, swelling of injected joints was common and was thought to be associated with death of stem cells. Also, tenosinovitis and tendonitis in elderly patients, all of which were either self-limited or were remedied with simple therapeutic measures, were common as well. CONCLUSIONS: Using both MRI tracking and telephone follow ups in 100 joints in 91 patients treated, no neoplastic complications were detected at any ADSC implantation sites. Based on our longitudinal cohort, the autologous and uncultured ADSCs/PRP therapy in the form of SVF could be considered to be safe when used as percutaneous local injections. BioMed Central 2013-12-01 /pmc/articles/PMC4219585/ /pubmed/24289766 http://dx.doi.org/10.1186/1471-2474-14-337 Text en Copyright © 2013 Pak et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pak, Jaewoo
Chang, Jae-Jin
Lee, Jung Hun
Lee, Sang Hee
Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints
title Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints
title_full Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints
title_fullStr Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints
title_full_unstemmed Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints
title_short Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints
title_sort safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219585/
https://www.ncbi.nlm.nih.gov/pubmed/24289766
http://dx.doi.org/10.1186/1471-2474-14-337
work_keys_str_mv AT pakjaewoo safetyreportingonimplantationofautologousadiposetissuederivedstemcellswithplateletrichplasmaintohumanarticularjoints
AT changjaejin safetyreportingonimplantationofautologousadiposetissuederivedstemcellswithplateletrichplasmaintohumanarticularjoints
AT leejunghun safetyreportingonimplantationofautologousadiposetissuederivedstemcellswithplateletrichplasmaintohumanarticularjoints
AT leesanghee safetyreportingonimplantationofautologousadiposetissuederivedstemcellswithplateletrichplasmaintohumanarticularjoints